Clinical trials: Stage II Adult Soft Tissue Sarcoma
Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
The purpose of the study is to investigate whether a personalized selection of patients with localized soft tissue sarcoma for preoperative proton radiation therapy can reduce long-term radiation side effects without increasing…
- Conditions
- Soft Tissue Sarcoma (Excluding GIST), Soft Tissue Sarcoma Adult, Soft Tissue Sarcoma of the Trunk and Extremities, Synovial Sarcomas
- Trial name
- PROSARC-1 (NCT07169344)
- Testing
- preoperative, Quality of life, Functional outcome
- Where
- 4 sites in Norway
- Volunteers
- 110 people
- Sponsor
- Oslo University Hospital
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Sarcoma
Bevacizumab in Treating Patients With Angiosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00288015
- Testing
- Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Liposarcomas are soft tissue sarcomas most frequent. We distinguish three subtypes on the basis of their histological and cytogenetic characteristics: well-differentiated liposarcoma / dedifferentiated, myxoid liposarcoma and /…
- Trial name
- APLIPO (NCT01876043)
- Testing
- plitidepsin
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Bergonié
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Leukemia, Lymphoma
Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus
RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus.
- Conditions
- Leukemia, Lymphoma, Precancerous Condition, Small Intestine Cancer
- Trial name
- NCT00006340
- Testing
- arginine butyrate, ganciclovir
- Where
- 6 sites in United States, France and 2 more
- Sponsor
- Boston Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
This phase I/II trial studies whether stopping cyclosporine before mycophenolate mofetil is better at reducing the risk of life-threatening graft-versus-host disease (GVHD) than the previous approach where mycophenolate mofetil…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00078858
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Fred Hutchinson Cancer Center
Sarcoma
Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00740597
- Testing
- gene expression analysis, polymerase chain reaction, western blotting
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
This randomized pilot clinical trial studies pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma.
- Conditions
- Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT01446809
- Testing
- Doxorubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
Breast Cancer, Chronic Myeloproliferative Disorders
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with cancer that has recurred following bone marrow or peripheral stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003887
- Testing
- peripheral blood lymphocyte therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Adult Liposarcoma, Metastatic Liposarcoma
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.
- Conditions
- Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT02357810
- Testing
- Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 178 people
- Sponsor
- Northwestern University
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells.
- Trial name
- NCT00019188
- Testing
- interleukin-12
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Solid Tumours
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
The study design was an open-label Phase II pediatric clinical study. The purpose of Study X2203 was to identify any efficacy signal in subjects with the disease subtypes under study, when treated with pazopanib monotherapy.
- Trial name
- NCT01956669
- Testing
- Pazopanib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00612716
- Testing
- busulfan, cyclophosphamide, Stem cell infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Sarcoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002995
- Testing
- dactinomycin, filgrastim, sargramostim
- Where
- 233 sites in United States, Australia and 5 more
- Volunteers
- 483 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Sirolimus, tacrolimus, and methotrexate may be effective in preventing acute graft-versus-host disease in patients who are undergoing donor stem cell transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00089037
- Testing
- methotrexate, sirolimus, tacrolimus
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center